Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 23-31 , January 2004

The Na+/I− symporter (NIS): imaging and therapeutic applications

  • Ekaterina Dadachova

      Affiliations

    • Departments of Nuclear Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA
    • ,
  • Nancy Carrasco

      Affiliations

    • Departments of Nuclear Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationAddress reprint requests to Dr. Nancy Carrasco, Department of Nuclear Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461., USA

References 

  1. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta. 1993;1154:65–82
  2. De La Vieja A, Dohan O, Levy O, et al.  Molecular analysis of the sodium/iodide symporter (Impact on thyroid and extrathyroid pathophysiology). Physiol Rev. 2000;80:1083–1105
  3. Dohán O, De La Vieja A, Paroder V, et al.  The sodium/iodide symporter (NIS) (Characterization, regulation, and medical significance). End Rev Endocr Rev. 2003;24:48–77
  4. Mazaferri EL. Carcinoma of the follicular epithelium. In:  Braverman LE,  Utiger R editor. The Thyroid (A Fundamental and Clinical Text). (ed 8).. Philadelphia, PA: Lippincott; 2000;p. 904–930
  5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–460
  6. Levy O, Dai G, Riedel C, et al.  Characterization of the thyroid Na+/I− symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci U S A. 1997;94:5568–5573
  7. Levy O, De la Vieja A, Ginter CS, et al.  N-linked glycosylation of the thyroid Na+/I− symporter (NIS). Implications for its secondary structure model. J Biol Chem. 1998;273:22657–22663
  8. Smanik PA, Liu Q, Furminger TL, et al.  Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun. 1996;226:339–345
  9. Everett LA, Belyantseva IA, Noben-Trauth K, et al.  Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. Hum Mol Genet. 2001;10:153–161
  10. Rodriguez AM, Perron B, Lacroix L, et al.  Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab. 2002;87:3500–3503
  11. Tazebay UH, Wapnir IL, Levy O, et al.  The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871–878
  12. Kogai T, Schultz JJ, Johnson LS, et al.  Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A. 2000;97:8519–8524
  13. Wapnir IL, van de Rijn M, Nowels K, et al.  Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003;88:1880–1888
  14. Moon DH, Lee SJ, Park KY, et al.  Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol. 2001;28:829–834
  15. Groot-Wassink T, Aboagye EO, Glaser M, et al.  Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther. 2002;13:1723–1735
  16. Shimura H, Haraguchi K, Miyazaki A, et al.  Iodide uptake and experimental 131-I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. Endocrinology. 1997;138:4493–4496
  17. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661–668
  18. Boland A, Ricard M, Opolon P, et al.  Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000;60:3484–3492
  19. Cho JY, Xing S, Liu X, et al.  Expression and activity of human Na+/I− symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. 2000;7:740–749
  20. Nakamoto Y, Saga T, Misaki T, et al.  Establishment and characterization of a breast cancer cell line expressing Na+/I− symporters for radioiodide concentrator gene therapy. J Nucl Med. 2000;41:1898–1904
  21. Sieger S, Jiang S, Schonsiegel F, et al.  Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging. 2003;30:748–756
  22. Haberkorn U, Kinscherf R, Kissel M, et al.  Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003;10:774–780
  23. Boland A, Magnon C, Filetti S, et al.  Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid. 2002;12:19–26
  24. Daniels GH, Haber DA. Will radioiodine be useful in treatment of breast cancer?. Nature Med. 2000;6:859–860
  25. Taurog AM. Hormone synthesis (Thyroid iodine metabolism). In:  Braverman LE,  Utiger RD editor. The Thyroid (A Fundamental and Clinical Text). (ed 8).. Philadelphia, PA: Lippincott, Williams and Wilkins; 2000;p. 61–85
  26. Maxon HR, Thomas SR, Hertzberg VS, et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941
  27. Huang M, Batra RK, Kogai T, et al.  Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 2001;8:612–618
  28. Smit JWA, Schröder-van der Elst JP, Karperien M, et al.  Iodide kinetics and experimental 131-I therapy in a xenotransplanted human sodium-iodide symporter-Transfected human follicular thyroid carcinoma cell line. J Clin Endocrin Metabol. 2002;87:1247–1253
  29. Cho JY, Shen DH, Yang W, et al.  In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther. 2002;9:1139–1145
  30. Kogai T, Schultz J, Johnson LS, et al.  Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A. 2000;97:8519–8524
  31. Spitzweg C, O’Connor MK, Bergert ER, et al.  Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526–6530
  32. Spitzweg C, Dietz AB, O’Connor MK, et al.  In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8:1524–1531
  33. Dingli D, Diaz RM, Bergert EK, et al.  Genetically targeted radiotherapy for multiple myeloma. Blood. 2003;102:489–496
  34. Saha GP. In: Fundamentals of nuclear pharmacy. New York, NY: Springer; 1997;p. 249
  35. Deutsch E, Libson K, Vanderheyden JL, et al.  The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B. 1986;13:465–477
  36. Zuckier LS, Dadachova E, Li Y, et al.  Comparative biodistribution of perrhenate, pertechnetate and iodide in NIS-expressing and non-expressing tissues of mice. J Nucl Med. 2001;42(suppl):325; abstr
  37. Dadachova E, Bouzahzah B, Zuckier LS, et al.  Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 2002;29:13–18
  38. Knapp FF. Rhenium-188-A generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 1998;13:337–349
  39. O’Donoghue JA, Bardiès M, Wheldon TE. Relationship between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  40. Dadachova E, Russell R, Zuckier LS. Assessment of maximal tolerated dose of 188Re-perrhenate, a potential agent for treatment of NIS-expressing tumors, in a mouse model. J Nucl Med. 2002;43(suppl):120; abstr
  41. Kang JH, Chung J-K, Lee YJ, et al.  Application of radionuclide gene therapy to human hepatocellular carcinoma cell line using sodium/iodide symporter. J Nucl Med. 2002;44(suppl):336; abstr
  42. Shen DH, Marsee DK, Yang W, et al.  188Re-perrhenate treatment to enhance the survival of rats bearing intracerebral sodium-iodide symporter transduced gliomas. J Nucl Med. 2003;44(suppl):35; abstr
  43. Lindencrona A, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211-At and 125-I transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001;28:41–50
  44. Carlin S, Mairs RJ, Welsh P, et al.  Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. Nucl Med Biol. 2002;29:729–739
  45. Petrich T, Helmeke HJ, Meyer GJ, et al.  Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2002;29:842–854
  46. Schmutzler C, Köhrle J. Implications of the molecular characterizations on the sodium-iodide symporter (NIS). Exp Clin Endocrinol Diabetes. 1998;106:S1–S10
  47. Spitzweg C, Heufelder AE. The sodium iodide symporter (Its emerging relevance to clinical thyroidology). Eur J Endocrinol. 1998;138:374–375
  48. Dohán O, De La Vieja A, Carrasco N. Molecular study of the sodium-iodide symporter (NIS) (A new field in thyroidology). Trends Endocrinol Metab. 2000;11:99–105
  49. Riedel C, Dohan O, De la Vieja A, et al.  Journey of the iodide transporter NIS (From its molecular identification to its clinical role in cancer). Trends Biochem Sci. 2001;26:490–496
  50. Spitzweg C, Morris JC. Approaches to gene therapy with sodium/iodide symporter. Exp Clin Endocrinol Diabetes. 2001;109:56–59
  51. Spitzweg C, Harrington KJ, Pinke LA, et al.  Clinical review 132 (The sodium iodide symporter and its potential role in cancer therapy). J Clin Endocrinol Metab. 2001;86:3327–3335
  52. Spitzweg C, Morris JC. The sodium iodide symporter (Its pathophysiological and therapeutic implications). Clin Endocrinol. 2002;57:559–574

PII: S0001-2998(03)00070-9

doi: 10.1053/j.semnuclmed.2003.09.004

Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 23-31 , January 2004

Article Tools

* Image Usage & Resolution